News
SNY
43.93
+0.50%
0.22
U.K. regulator reaffirms safety of childhood vaccination
Seeking Alpha · 1d ago
Prime Medicine: An Initial Prognosis
Seeking Alpha · 1d ago
Sanofi price target lowered to EUR 82 from EUR 86 at Morgan Stanley
TipRanks · 1d ago
Trump Cuts Core Childhood Vaccine Recommendations to 11, Bill Cassidy Says 'This Executive Order Is Wrong'
Benzinga · 2d ago
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
Seeking Alpha · 2d ago
Trump executive order set to make major changes to childhood vaccines schedule
Seeking Alpha · 2d ago
Midday Fly By: Intel announces $15B offering, Meta unveils Muse Glimmer
TipRanks · 3d ago
Sanofi facing shortages of two drugs for Pompe disease, STAT reports
TipRanks · 3d ago
Weekly Report: what happened at SNY last week (0803-0807)?
Weekly Report · 3d ago
Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data
NASDAQ · 6d ago
Sanofi, Regeneron Seem Keen to Keep Working Together -- Market Talk
Dow Jones · 6d ago
Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX
NASDAQ · 6d ago
Trump weighs executive order on vaccines and autism - report
Seeking Alpha · 6d ago
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
NASDAQ · 6d ago
Novavax raises 2026 revenue outlook after Q2 beat
Seeking Alpha · 08/06 12:51
Sanofi: How I Leveraged This Undervalued Dividend Aristocrat
Seeking Alpha · 08/06 10:13
Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan
Seeking Alpha · 08/05 20:05
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (August 2026)
Seeking Alpha · 08/05 12:24
Nurix Therapeutics Earns $10M Milestone Payment Following Initiation Of Sanofi's Phase 1 Clinical Study Of SAR448272/NX-3911
Benzinga · 08/04 11:14
Sanofi’s MenQuadfi approved in EU for infants against meningococcal disease
Seeking Alpha · 08/04 09:12
More
Webull provides a variety of real-time SNY stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.